3 guideline điều trị suy tim theo VNHA 2022

KHUYẾN CÁO CỦA HỘI TIM MẠCH QUỐC GIA VỀ CHẨN ĐOÁN VÀ ĐIỀU TRỊ SUY TIM CẤP VÀ SUY TIM MẠN (2022) Trưởng ban: PGS TS Phạm Nguyễn Vinh Đồng trưởng ban: PGS TS Phạm Mạnh Hùng THAM GIA BIÊN SOẠN: GS.TS Đặng Vạn Phước; GS.TS Nguyễn Lân Việt; GS.TS Huỳnh Văn Minh; GS.TS Trương Quang Bình; GS.TS Đỗ Doãn Lợi; PGS.TS Châu Ngọc Hoa; PGS.TS Nguyễn Ngọc Quang; PGS.TS Đỗ Quang Hn; PGS.TS Hồng Quốc Hịa; PGS.TS Hồ Thượng Dũng; PGS.TS Trần Văn Huy; TS.BS Trần Vũ Minh Thư; TS.BS Hồng Văn Sỹ; TS.BS Phan Đình Phong; TS.BS Phan Tuấn Đạt; TS.BS Đinh Đức Huy; TS.BS Nguyễn Thị Thu Hoài; BS.CK2 Nguyễn Thanh Hiền; BS.CK2 Lê Thị Đẹp; BS.CK1 Phạm Thục Minh Thủy; ThS.BS Huỳnh Thanh Kiều; ThS.BS Đỗ Thúy Cẩn; ThS.BS Lê Võ Kiên; ThS.BS Phạm Nhật Minh; ThS.BS Nguyễn Phương Anh; ThS BS Trần Tuấn Việt M CL C N: C L C C CÁC T T T T C HÌNH NH 10 C CÁC B NG 11 u: ch t i 13 13 y tim 14 D ch t nt 14 15 15 3.1 16 Ch 4.1 n 18 18 c ch u 4.3 h nv tt m ng thu c 5.1 ng c 36 Suy tim v 6.1 Ch tt mv m nh 45 tt m nh 45 tt tt 6.3 7.1 m nh 45 m nh 45 tt o t n 49 Gi i thi u 49 49 tt 7.3 7.4 7.5 Ch tt tt o t n 49 o t n 50 o t n 55 Suy tim nặng - Giai đoạn D 56 ng 56 8.1 D ch t 59 Suy tim cấp 69 Dịch tễ học 69 9.2 Sinh lý bệnh suy tim cấp .70 9.3 Chẩn đoán 70 9.4 Biểu lâm sàng 72 9.5 Điều trị 78 10 9.1 Các bệnh tim mạch đồng mắc 83 10.1 Loạn nhịp rối loạn dẫn truyền 83 10.2 Hội chứng mạch vành mạn 88 10.3 Bệnh van tim 91 10.4 Tăng huyết áp 96 10.5 Đột quỵ 97 11 Bệnh đồng mắc không tim mạch 98 11.1 Đái tháo đường (tiểu đường) 98 11.2 Rối loạn chức tuyến giáp 98 11.3 Béo phì 99 11.4 Cơ thể suy nhược (fraily), suy kiệt (cachexia) giảm thiểu vân (sarcopenia) 99 11.5 Thiếu sắt thiếu máu .100 11.6 Rối loạn chức thận 100 11.7 Rối loạn điện giải: Kali máu thấp, kali máu cao, natri máu thấp, natri máu cao 100 11.8 Bệnh phổi mạn bệnh hô hấp liên quan đến giấc ngủ .101 11.9 Gút viêm khớp 102 11.10 Rối loạn cương dương .102 11.11 Trầm cảm 102 11.12 Ung thư 102 11.13 Nhiễm trùng .105 12 Các tình trạng đặc biệt 105 12.1 Thai kỳ .105 12.2 Các bệnh tim 107 12.3 Bệnh tim bẩm sinh người lớn .131 13 Quản lý suy tim mạn đa chuyên khoa (QLSTĐCK) 135 13.1 Phòng ngừa suy tim 135 13.2 Các mơ hình chăm sóc .135 13.3 Nguyên tắc thành phần Chương trình quản lý suy tim 135 13.4 Giáo dục sức khoẻ, tự chăm sóc thay đổi lối sống 136 13.5 Tập luyện phục hồi chức 137 13.6 Theo dõi bệnh nhân suy tim mạn tính 137 13.7 Theo dõi từ xa (TDTX) .138 TÀI LIỆU THAM KHẢO 139 DANH M C CÁC T T vi t t t Ti ng Anh 5- 5- VI T T T Ti ng vi t ACC H i Tim m ch h ACE- c ch - ACHD B n AF AHA Hi p h ANA - ANCA ARB Ch n th th - c ch - - ARVC BCT - B BCTDN - B BCTKLC Non-compaction cardyomyopathy Bệnh tim không lèn chặt - B BCTSLN - B BNP B- - i n nh p BTB C un it ic un i BTC C un it BTD C u n i t i quy BTR C u n i t i h i ph c BTT C un u nh c y ghép B nh tim thi - BUN - C CABG -A - c c u ch - CARE-HF Thi - - CHS CHT CK - C ng t - -HF HF B nh ph i m n t c ngh n CPAP - CR CRT tim CRT-D Li tim v kh CRT-P Li tim v t o nh p tim CSA CT Ch p c - DAPA-HF u DAPA-HF ECG Tu EF tt c c u th EHRA H i Nh p h c Châu Âu châu Âu - - ESC Hi p h i Tim m ch châu Âu FAC FHS u ph i h p FHS HFA-ESC H i tim m ch châu Âu - ) Suy tim v gi m nh Suy tim v o t n) tt o t n Suy tim v gi m) tt tt gi m cho h D - K tu c ut nh Không LGE nv LVAD Thi LVEF h th tt -CRT -CRT H tu c -FR -FR th - Nh NP i ni u N- NT- -B- - NYHA t c ngh n ng -HF u PEP-CHF RAAS c u PEP-CHF - tt - tt - - H th - RAFT RASi - u RAFT - c ch h - RATE-AF u RATE-AF REVERSE u REVERSE SAVR ng ph u thu t - S8 -HF - Ch t c ch nc ng v n chuy - SPECT single-photon emission CT Chụp xạ hình chùm đơn photon STC - Suy tim cấp STMMBC - Suy tim mạn bù cấp STPSTM - Suy tim với phân suất tống máu STS-PROM Society of Thoracic Surgeons Predicted Risk of Mortality Điểm STS-PROM TAPSE Tricuspid annular plane systolic excursion Vận động vịng van ba tâm thu TAVI Transcatheter aortic valve implantation Thay van ĐMC qua da Tc technetium Chụp xạ hình với technetium ƯCMC - Ức chế men chuyển ƯCTT - Ức chế thụ thể VEGF Vascular endothelial growth factor Yếu tố tăng trưởng nội mô mạch máu VNTMNT - Viêm nội tâm mạc nhiễm trùng VPB Ventricular premature beat Ngoại tâm thu thất WCD Wearable Cardioverter-Defibrillator Áo phá rung chuyển nhịp XL Extended release Phóng thích kéo dài DANH MỤC HÌNH ẢNH Hình Định nghĩa tồn cầu suy tim Hình Nồng độ peptide niệu trợ giúp chẩn đoán suy tim Hình Qui trình chẩn đốn suy tim Hình Qui trình điều trị suy tim phân suất tống máu giảm Hình Điều trị suy tim phân suất tống máu giảm dựa kiểu hình bệnh Hình Chẩn đoán STPSTM bảo tồn dựa vào tháng điểm HFA-PEFF Hình Bước (F): Trắc nghiệm chức trường hợp chẩn đốn khơng chắn Hình Qui trình điều trị suy tim nặng Hình Phân loại bệnh nhân suy tim nặng xác định thời gian chuyển tuyến Hình 10 Sơ đồ sinh lý bệnh suy tim cấp Hình 11 Sơ đồ chẩn đốn suy tim cấp khởi phát Hình 12 Xử trí suy tim bù cấp Hình 13 Xử trí bệnh nhân phù phổi Hình 14 Xử trí bệnh nhân suy thất phải đơn độc Hình 15 Xử trí bệnh nhân sốc tim Hình 16 Tiếp cận ban đầu suy tim cấp Hình 17 Điều trị lợi tiểu (furosemide) suy tim cấp Hình 18 Điều trị rung nhĩ bệnh nhân suy tim Hình 19 Điều trị nội khoa hội chứng mạch vành mạn bệnh nhân STPSTM giảm Hình 20 Xử trí bệnh nhận hẹp van ĐMC nặng kèm lưu lượng thấp độ chênh áp thấp Hình 21 Xử trí hở van hai thứ phát bệnh nhân suy tim giảm phân suất tống máu Hình 22 Xử trí bệnh nhân ung thư suy tim Hình 23 Xử trí bệnh nhân suy tim trước có thai Hình 24 Các giai đoạn bệnh tâm nhĩ Hình 25 MRI 4D giúp khảo sát dịng máu nhĩ bệnh nhân có rung nhĩ Hình 26 Lưu đồ quản lý suy tim nghi viêm tim Hình 27 Chẩn đốn điều trị suy tim bệnh amyloidosis Hình 28 Bệnh tim bẩm sinh bệnh mạn tính cần theo dõi điều trị suốt đời 10 28 van Veldhuisen DJ, Cohen-Solal A, Bohm M, Anker SD et al Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure) J Am Coll Cardiol 2009;53:2150-2158 29 Solomon SD, Claggett B, Lewis EF et al TOPCAT Investigators Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction Eur Heart J 2016;37:455-462 30 Solomon SD, McMurray JJV, Anand IS et al PARAGON-HF Investigators and Committees Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction N Engl J Med 2019;381:1609-1620 31 Solomon SD, Vaduganathan M, Claggett BL et al Sacubitril/valsartan across the spectrum of ejection fraction in heart failure Circulation 2020;141:352-361 32 Anker SD, Butler J, Filippatos G et al Empagliflozin in Heart Failure with a Preserved Ejection Fraction the EMPEROR-Preserved Trial n engl j med DOI: 10.1056/NEJMoa2107038 33 Cleland JGF, Bunting KV, Flather MD et al Beta-blockers for heart failure with reduced, midrange, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials Eur Heart J 2018;39:26-35 34 Shah SJ, Feldman T, Ricciardi MJ et al One year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: a randomized clinical trial JAMA Cardiol 2018;3:968-977 35 Borlaug BA: Treatment and prognosis of heart failure with mid-range ejection fraction Uptodate 2021 36 Adelstein E, Saba SM Cardiac resynchronization therapy in heart failure: Indications Uptodate 2021 37 Borlaug BA Evaluation and management of heart failure with preserved ejection fraction Nat Rev Cardiol 2020;17:559-573 38 Kini V, Soufi MK, Deo R, et al Appropriateness of primary prevention implantable cardioverterdefibrillators at the time of generator replacement: are indications still met? J Am Coll Cardiol 2014;63:2388-2394 39 Reddy YNV, Carter RE, Obokata M, et al A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction Circulation 2018;138:861-870 141 40 Pieske B, Tschope C, de Boer RA et al How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) Eur Heart J 2019;40:3297-3317 41 Stevenson LW, Pagani FD, Young JB, Jessup M, Miller L, Kormos RL, Naftel DC, Ulisney K, Desvigne-Nickens P, Kirklin JK INTERMACS profiles of advanced heart failure: the current picture J Heart Lung Transplant 2009;28:535-541 42 Barandiaran Aizpurua A, Sanders-van Wijk S et al Validation of the HFA-PEFF score for the diagnosis of heart failure with preserved ejection fraction Eur J Heart Fail 2020;22:413-421 43 Halliday BP, Wassall R, Lota AS, et al Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial Lancet 2019;393:61-73 44 Tsutsui H, Isobe M, Ito H et al JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure Circ J 2019 Sep 25;83(10):2084-2184 45 Faris R, Flather M, Purcell H, et al Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials Int J Cardiol 2002;82:149-158 46 Kjekshus J, Pedersen TR, Olsson AG, et al The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease J Card Fail 1997;3:249-254 47 Scirica BM, Morrow DA, Cannon CP, et al Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study J Am Coll Cardiol 2006;47:2326-2331 48 Cannon CP, Pratley R, Dagogo-Jack S et al VERTIS CV Investigators Cardiovascular outcomes with ertugliflozin in type diabetes N Engl J Med 2020;383:1425-1435 49 Neal B, Perkovic V, Mahaffey KW et al CANVAS Program Collaborative Group Canagliflozin and cardiovascular and renal events in type diabetes N Engl J Med 2017;377:644-657 50 Wiviott SD, Raz I, Bonaca MP, et al DECLARE-TIMI 58 Investigators Dapagliflozin and cardiovascular outcomes in type diabetes N Engl J Med 2019;380:347-357 51 Zinman B, Wanner C, Lachin JM et al EMPA-REG OUTCOME Investigators Empagliflozin, cardiovascular outcomes, and mortality in type diabetes N Engl J Med 2015;373:2117-2128 52 Dorans KS, Mostofsky E, Levitan EB, et al Alcohol and incident heart failure among middleaged and elderly men: cohort of Swedish men Circ Heart Fail 2015;8:422-427 53 Goncalves A, Claggett B, Jhund PS, et al Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study Eur Heart J 2015;36:939-945 142 54 Padwal R, McAlister FA, McMurray JJ, et al Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data Int J Obes (Lond) 2014;38:11101114 55 Pandey A, Garg S, Khunger M, et al Dose-response relationship between physical activity and risk of heart failure: a meta-analysis Circulation 2015;132:1786-1794 56 Rose EA, Gelijns AC, Moskowitz AJ et al Long-term use of a left ventricular assist device for end-stage heart failure N Engl J Med 2001;345:1435-1443 57 Rogers JG, Butler J, Lansman SL et al Chronic mechanical circulatory support for inotropedependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial J Am Coll Cardiol 2007;50:741-747 58 Starling RC, Estep JD, Horstmanshof DA et al Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: the ROADMAP study 2-year results JACC Heart Fail 2017;5:518-527 59 Rogers JG, Pagani FD, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ, Boyce SW, Najjar SS, Jeevanandam V, Anderson AS, Gregoric ID, Mallidi H, Leadley K, Aaronson KD, Frazier OH, Milano CA Intrapericardial left ventricular assist device for advanced heart failure N Engl J Med 2017;376:451-460 60 Mehra MR, Uriel N, Naka Y et al A fully magnetically levitated left ventricular assist device – final report N Engl J Med 2019;380:1618-1627 61 Slaughter MS, Pagani FD, McGee EC et al HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial J Heart Lung Transplant 2013;32:675-683 62 Karason K, Lund LH, Dalen M et al Rationale and design of the SWEdish evaluation of left Ventricular Assist Device (SweVAD) trial Eur J Heart Fail 2020;22:739-750 63 Thiele H, Zeymer U, Thelemann N et al Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction: long-term 6-year outcome of the randomized IABPSHOCK II Trial Circulation 2019;139:395-403 64 Van Gelder IC, Groenveld HF, Crijns HJ et al Lenient versus strict rate control in patients with atrial fibrillation N Engl J Med 2010;362:1363-1373 65 Kotecha D, Bunting KV, Gill SK et al Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial JAMA 2020;324:2497-2508 66 Abdelrahman M, Subzposh FA, Beer D et al Clinical outcomes of His bundle pacing compared to right ventricular pacing J Am Coll Cardiol 2018;71:2319-233 143 67 Suskin N, Sheth T, Negassa A, Yusuf S Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction J Am Coll Cardiol 2001;37:16771682 68 Kirchhof P, Camm AJ, Goette A et al Early rhythm-control therapy in patients with atrial fibrillation N Engl J Med 2020;383:1305-1316 69 Marrouche NF, Brachmann J, Andresen D et al Catheter ablation for atrial fibrillation with heart failure N Engl J Med 2018;378:417-427 70 Packer DL, Mark DB, Robb RA et al Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial JAMA 2019;321:1261-1274 71 Kuck KH, Merkely B, Zahn R et al Catheter ablation versus best medical therapy in patients with persistent atrial fibrillation and congestive heart failure: the randomized AMICA trial Circ Arrhythm Electrophysiol 2019;12:e007731 72 Di Biase L, Mohanty P, Mohanty S et al Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial Circulation 2016;133:1637-1644 73 Zannad F, Anker SD, Byra WM et al Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease N Engl J Med 2018;379: 1332-1342 74 Velazquez EJ, Lee KL, Deja MA et al Coronary-artery bypass surgery in patients with left ventricular dysfunction N Engl J Med 2011;364:1607-1616 75 Cleland JG, Calvert M, Freemantle N et al The Heart Failure Revascularisation Trial (HEART) Eur J Heart Fail 2011;13:227-233 76 Perera D, Clayton T, Petrie MC et al Percutaneous revascularization for ischemic ventricular dysfunction: rationale and design of the REVIVED-BCIS2 trial: percutaneous coronary intervention for ischemic cardiomyopathy JACC Heart Fail 2018;6:517-526 77 Obadia JF, Messika-Zeitoun D, Leurent G et al Percutaneous repair or medical treatment for secondary mitral regurgitation N Engl J Med 2018;379:22972306 78 Iung B, Armoiry X, Vahanian A et al Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at years Eur J Heart Fail 2019;21:16191627 79 Stone GW, Lindenfeld J, Abraham WT et al Transcatheter mitral-valve repair in patients with heart failure N Engl J Med 2018;379:23072318 80 Mehra MR, Vaduganathan M, Fu M et al A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial Eur Heart J 2019;40:3593-3602 144 81 Seferović PM, Coats AJS, Ponikowski P et al European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure Eur J Heart Fail 2020 Feb;22(2):196-213 82 Roumie CL, Min JY, D’Agostino McGowan et al Comparative safety of sulfonylurea and metformin monotherapy on the risk of heart failure: a cohort study J Am Heart Assoc 2017;6 83 Lago RM, Singh PP, Nesto RW Congestive heart failure and cardiovascular death in patients with prediabetes and type diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials Lancet 2007;370:1129-1136 84 McMurray JJV, Solomon SD, Inzucchi SE et al Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction N Engl J Med 2019 Nov 21;381(21):1995-2008 85 Packer M, Anker SD, Butler J et al Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial Circulation 2021 Jan 26;143(4):326-336 86 Sato Y, Yoshihisa A, Kimishima Y et al Low T3 Syndrome Is Associated With High Mortality in Hospitalized Patients With Heart Failure J Card Fail 2019 Mar;25(3):195-203 87 Stott DJ, Rodondi N, Kearney PM et al Thyroid hormone therapy for older adults with subclinical hypothyroidism N Engl J Med 2017;376:2534-2544 88 Peeters RP Subclinical hypothyroidism N Engl J Med 2017;376:2556-2565 89 Kitzman DW, Brubaker P, Morgan T et al Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial JAMA 2016;315:36-46 90 Carbone S, Lavie CJ, Arena R Obesity and heart failure: focus on the obesity paradox Mayo Clin Proc 2017;92:266-279 91 Bielecka-Dabrowa A, Ebner N, Dos Santos MR et al Cachexia, muscle wasting, and frailty in cardiovascular disease Eur J Heart Fail 2020;22:2314-2326 92 Vitale C, Jankowska E, Hill L et al Heart Failure Association/European Society of Cardiology position paper on frailty in patients with heart failure Eur J Heart Fail 2019;21:1299-1305 93 Bauer J, Morley JE, Schols A et al Sarcopenia: a time for action An SCWD position paper J Cachexia Sarcopenia Muscle 2019;10:956-961 94 Springer J, Springer JI, Anker SD Muscle wasting and sarcopenia in heart failure and beyond: update 2017 ESC Heart Fail 2017;4:492-498 95 Okonko DO, Mandal AK, Missouris CG et al Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival J Am Coll Cardiol 2011;58:1241-1251 145 96 Swedberg K, Young JB, Anand IS et al.Treatment of anemia with darbepoetin alfa in systolic heart failure N Engl J Med 2013;368:1210-1219 97 Zannad F, Ferreira JP, Pocock SJ et al Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced Circulation 2021;143:310-321 98 Heerspink HJL, Stefansson BV, Correa-Rotter R et al Dapagliflozin in patients with chronic kidney disease N Engl J Med 2020;383:1436-1446 99 Ferreira JP, Mogensen UM, Jhund PS et al Serum potassium in the PARADIGM-HF trial Eur J Heart Fail 2020;22:2056-2064 100 Rosano GMC, Spoletini I, Agewall S Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate Eur Heart J Suppl 2019;21:A28-A33 101 Cuthbert JJ, Pellicori P, Rigby A et al Low serum chloride in patients with chronic heart failure: clinical associations and prognostic significance Eur J Heart Fail 2018;20:1426-1435 102 Anberg JS, Rao V, Ter Maaten JM et al Hypochloremia and diuretic resistance in heart failure: mechanistic insights Circ Heart Fail 2016;9 103 Verbrugge FH, Martens P, Ameloot K et al Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance Eur J Heart Fail 2019;21:1415-1422 104 Global Initiative for Chronic Obstructive Lung Disease Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2020 report 2020FINAL-ver1.2-03Dec19_WMV.pdf (31 May 2020) 105 Global Initiative for Asthma Global Strategy for Asthma Management and Prevention, 2019 www.ginasthma.org (28 May 2021) 106 Pearse SG, Cowie MR Sleep-disordered breathing in heart failure Eur J Heart Fail 2016;18:353361 107 Cowie MR, Gallagher AM Sleep disordered breathing and heart failure: what does the future hold? JACC Heart Fail 2017;5:715-723 108 Huang H, Huang B, Li Y et al Uric acid and risk of heart failure: a systematic review and metaanalysis Eur J Heart Fail 2014;16:15-24 109 White WB, Saag KG, Becker MA et al Cardiovascular safety of febuxostat or allopurinol in patients with gout N Engl J Med 2018;378:1200-1210 110 Jaarsma T Sexual function of patients with heart failure: facts and numbers ESC Heart Fail 2017;4:3-7 111 Jha MK, Qamar A, Vaduganathan M, Charney DS et al Screening and management of depression in patients with cardiovascular disease: JACC state-of-the-art review J Am Coll Cardiol 2019;73:1827-1845 146 112 Boekel NB, Duane FK, Jacobse JN et al Heart failure after treatment for breast cancer Eur J Heart Fail 2020;22:366-374 113 Banke A, Schou M, Videbaek L et al Incidence of cancer in patients with chronic heart failure: a long-term follow-up study Eur J Heart Fail 2016;18:260-266 114 Celutkiene J, Pudil R, Lopez-Fernandez et al Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC) Eur J Heart Fail 2020;22:1504-1524.113 115 Gotsman I, Shuvy M, Tahiroglu I et al Influenza vaccination and outcome in heart failure Am J Cardiol 2020;128:134-139 116 Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy Eur Heart J 2018;39:3165-3241 117 Bauersachs J, Konig T, van der Meer P et al Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy Eur J Heart Fail 2019;21:827-843 118 Stapel B, Kohlhaas M, Ricke-Hoch M et al Low STAT3 expression sensitizes to toxic effects of beta-adrenergic receptor stimulation in peripartum cardiomyopathy Eur Heart J 2017;38:349361 119 Hilfiker-Kleiner D, Haghikia A, Berliner D et al Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study Eur Heart J 2017;38:2671-2679 120 Braunwald E (2017), “Cardiomyopathies an overview”, Circ Res, 121, pp 711–721 121 Ezekowitz J.A., O’Meara E, McDonald M.A., et al (2017), “2017 comprehensive update of the Canadian cardiovascular society guidelines for the management of heart failure”, Can J Cardiol, 33, pp 1342–1433 122 Seferovic PM, Polovina M, Bauersachs J et al Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail 2019;21:553-576 123 Falk R.H., Hershberger R.E (2019), “The Dilated, Restrictive, and Infiltrative Cardiomyopathies”, Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 11th ed, Elsevier Inc, chapter 77,1580-1601 124 Aleksovaa N., Rutberga J., Green M., (2017), “Genetic testing in cardiomyopathies: an update on indications and benefits”, Curr Opin Cardiol, 32, pp 189–195 147 125 Leone O, Veinot JP, Angelini A, Baandrup UT et al 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology Cardiovasc Pathol 2012;21:245274 126 McKenna W.J., Maron B.J., Thiene G (2017), “Classification, epidemiology, and global burden of cardiomyopathies”, Circ Res.,121, pp 722–730 127 Pinto Y.M., Elliott P.M., Arbustini E., et al (2016), “Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases”, Eur Heart J, 37(23), pp 1850-1858 128 Maron B.J., Towbin J.A., Thiene G., et al (2006), “Contemporary definitions and classifi cation of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention”, Circulation, 113, pp 1807– 1816 129 Towbin J.A., Lowe A.M., Colan S.D., et al (2006), “Incidence, causes, and outcomes of dilated cardiomyopathy in children”, JAMA, 296, pp 1867–1876 130 Grunig E., Tasman J.A., Kucherer H., et al (1998), “Frequency and phenotypes of familial dilated cardiomyopathy”, J Am Coll Cardiol, 31, pp 186–194 131 Hershberger R.E., Siegfried J.D (2011), “Update 2011: clinical and genetic issues in familial dilated cardiomyopathy”, J Am Coll Cardiol, 57(16), pp 1641-1649 132 Halliday, B.P et al (2018), “Sex- and age- based difference sin the natural history and outcome of dilated cardiomyopathy”, Eur J Heart Fail, 20, 1392–1400 133 Dec G.W., Fuster V., (1994), “Idiopathic dilated cardiomyopathy”, N Engl J Med, 331, pp 1564– 1575 134 Rapezzi C., Arbustini E., Caforio A.L., et al (2013), “Diagnostic work-up in cardiomyopathies:bridging the gap between clinical phenotypes and final diagnosis A position statement from the ESC Working Group on Myocardial and Pericardial Diseases”, Eur Heart J, 34(19), pp 1448-1458 135 Hershberger R.E., Givertz M., Ho C.Y et al (2018), “Genetic Evaluation of Cardiomyopathy - a Heart Failure Society of America Practice Guideline”, J Card Fail, 24(5), pp 281-302 136 Al-Khatib S.M., Stevenson W.G., Ackerman M.J et al (2018), “2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death”, Circulation, 138, pp e272–e391 148 137 Lund L.H., Edwards L.B., Kucheryavaya A.Y., et al (2015), “The registry of the International Society for Heart and Lung Transplantation: thirty-second offi cial adult heart transplantation report—2015; focus theme: early graft failure”, J Heart Lung Transplant, 34, pp 1244–1254 138 Frustaci A., Russo M A., Chimenti, C (2009), “Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study”, Eur Heart J., 30, pp.1995–2002 139 Coppini R, Ho CY, Ashley E et al Clinical Phenotype and Outcome of Hypertrophic Cardiomyopathy Associated With Thin-Filament Gene Mutations J Am Coll Cardiol 2014;64:2589–2600 140 Elliott PM, Anastasakis A, Borger MA et al ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC) European Heart Journal 2014; doi:10.1093/eurheartj/ehu284 141 Maron BJ, Maron MS Hypertrophic cardiomyopathy Lancet.2013;381:242–255 142 Richard P, Charron P, Carrier L et al Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy Circulation 2003; 107:2227-2232 143 Trần Vũ Minh Thư, Nguyễn Thụy Vy, Phạm Nguyễn Vinh Nhân trường hợp bệnh tim phì đại tắc nghẽn, suy tim mang đột biến gene MYBPC3 Y học Thành phố Hồ Chí Minh 2018; 22(1), 129-13 144 Maron MS, Olivotto I, Zenovich AG et al Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction Circulation 2006;114: 2232-2239 145 Ommen SR, Mital S, Burke MA et al 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy Circulation 2020;142:e558–e631 146 Steve R Ommen, Seema Mital, Michael A Burke et al 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy Circulation 2020;142:e558–e631 147 Olivotto I, Oreziak A, Barriales-Villa R et al Mavacamten for treatment of symtomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase trial The lancet, 2020; 396:759-769 148 Corrado, D.; Basso, C.; Judge, D Arrhythmogenic Cardiomyopathy Circ Res 2017, 121, 784– 802 149 Rampazzo A, Nava A, Danieli GA et al The gene for arrhythmogenic right ventricular cardiomyopathy maps to chromosome 14q23-q24 Hum Mol Genet 1994 Jun;3(6):959-62 149 150 Thiene G, Corrado D, Nava A et al Right ventricular cardiomyopathy: is there evidence of an inflammatory aetiology? Eur Heart J 1991;12(suppl D):22–25 151 Hulot JS, Jouven X, Empana JP et al Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy Circulation 2004;110:1879–1884 doi: 10.1161/01 CIR.0000143375.93288.82 152 Corrado D, Basso C, Thiene G Arrhythmogenic right ventricular cardiomyopathy: diagnosis, prognosis, and treatment Heart 2000 May;83(5):588-95 153 Corrado, D.; Perazzolo Marra, M.; Zorzi, A et al Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria Int J Cardiol 2020, 319, 106–114 154 Corrado, D.; Wichter, T.; Link, M.S.; Hauer, R.N.; Marchlinski, F.E.; Anastasakis, A.; Bauce, B.; Basso, C.; Brunckhorst, C.; Tsatsopoulou, A.; et al Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia Circulation 2015, 132, 441–453 155 Thiene G, Corrado D, Basso C Arrhythmogenic right ventricular cardiomyopathy/dysplasia Orphanet J Rare Dis 2007 Nov 14;2:45 156 Fontaine G, Tonet J, Gallais Y, Lascault G, Hidden-Lucet F, Aouate P, Halimi F, Poulain F, Johnson N, Charfeddine H, Frank R Ventricular tachycardia catheter ablation in arrhythmogenic right ventricular dysplasia: a 16-year experience Curr Cardiol Rep 2000 Nov;2(6):498-506 157 Engberding R, Yelbuz TM, Breithardt G Isolated noncompaction of the left ventricular myocardium—a review of the literature two decades after the initial case description Clin Res Cardiol 2007; 96: 481–88 158 Towbin JA, Lorts A, Jefferies JL Left ventricular non-compaction cardiomyopathy Lancet 2015;386:813825 159 Klenda J, Boppana LKT, Vindhyal MR Heart Failure Secondary to Left Ventricular Noncompaction Cardiomyopathy in a 26-Year-Old Male Cureus 2018 Jul 20;10(7):e3011 160 Jenni R, Oechslin E, Schneider J, Attenhofer Jost C, Kaufmann PA Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-compaction: a step towards classifi cation as a distinct cardiomyopathy Heart 2001; 86: 666–71 161 Petersen SE, Selvanayagam JB, Wiesmann F, et al Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging J Am Coll Cardiol 2005; 46: 101–05 162 van Dalen BM, Caliskan K, Soliman OI, et al Left ventricular solid body rotation in noncompaction cardiomyopathy: a potential new objective and quantitative functional diagnostic criterion? Eur J Heart Fail 2008; 10: 1088–93 163 Paterick TE, Tajik AJ Left ventricular noncompaction: a diagnostically challenging cardiomyopathy Circ J 2012; 76: 1556–62 150 164 Zipes DP Atrial fibrillation A tachycardia-induced atrial cardiomyopathy Circulation 1997 Feb 4;95(3):562-4 165 Guo Y, Lip GY, Apostolakis S Inflammation in atrial fibrillation J Am Coll Cardiol 2012 Dec 4;60(22):2263-70 166 Shen MJ, Arora R, Jalife J et al Atrial Myopathy J Am Coll Cardiol Basic Trans Science 2019 Sep, (5) 640–654 167 Guichard JB, Nattel S Atrial Cardiomyopathy: A Useful Notion in Cardiac Disease Management or a Passing Fad? J Am Coll Cardiol 2017 Aug 8;70(6):756-765 168 Rohner A, Brinkert M, Kawel N et al unctional assessment of the left atrium by real-time threedimensional echocardiography using a novel dedicated analysis tool: initial validation studies in comparison with computed tomography Eur J Echocardiogr 2011 Jul;12(7):497-505 169 Marrouche NF, Wilber D, Hindricks G et al Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study JAMA 2014 Feb 5;311(5):498-506 170 Markl M, Lee DC, Ng J et al Left Atrial 4-Dimensional Flow Magnetic Resonance Imaging: Stasis and Velocity Mapping in Patients With Atrial Fibrillation Invest Radiol 2016;51(3):147154 171 Markl M, Lee DC, Furiasse N et al Left Atrial and Left Atrial Appendage 4D Blood Flow Dynamics in Atrial Fibrillation Circ Cardiovasc Imaging 2016 Sep;9(9):e004984 172 Fiedler, A Uber akute interstitielle Myokarditis Zentralblatt für Innere Med 21, 212–213 (1900) 173 Heymans S, Eriksson U, Lehtonen J, Cooper LT, Jr The quest for new approaches in myocarditis and inflammatory cardiomyopathy J Am Coll Cardiol 2016;68:23482364 174 Cooper LT Jr, Keren A, Sliwa K, Matsumori A, Mensah GA The global burden of myocarditis: part 1: a systematic literature review for the Global Burden of Diseases, Injuries, and Risk Factors 2010 study Glob Heart 2014 Mar;9(1):121-9 doi: 10.1016/j.gheart.2014.01.007 PMID: 25432122 175 Merken J, Hazebroek M, Van Paassen P Immunosuppressive therapy improves both short- and long-term prognosis in patients with virus-negative nonfulminant inflammatory cardiomyopathy Circ Heart Fail 2018;11:e004228 176 Banypersad SM, Moon JC, Whelan C et al Updates in Cardiac Amyloidosis: A Review 2012 https://doi.org/10.1161/JAHA.111.000364, Journal of the American Heart Association 2012;1: e000364 177 Kyle RA, Gertz MA Primary systemic amyloidosis: clinical and laboratory features in 474 cases Semin Hematol 1995 Jan;32(1):45-59 PMID: 7878478 151 178 I M Hamour,H J Lachmann,H J B Goodman,M Petrou,M M Burke,P N Hawkins,N R Banner, Heart Transplantation for Homozygous Familial Transthyretin (TTR) V122I Cardiac Amyloidosis,2008 https://doi.org/10.1111/j.1600-6143.2008.02162.x 179 Adams D, Gonzalez-Duarte A, O'Riordan W et al Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis, 2018, N Engl J Med 2018; 379:11-21 DOI: 10.1056/NEJMoa1716153 180 Adams D, Polydefkis M, González-Duarte A et al Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study, 2020 DOI:https://doi.org/10.1016/S1474-4422(20)30368-9 181 Aessopos A, Farmakis D, Deftereos S et al Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia Chest 2005 May;127(5):1523-30 doi: 10.1378/chest.127.5.1523 PMID: 15888823 182 Farmakis D, Triposkiadis F, Lekakis J, Parissis J Heart failure in haemoglobinopathies: pathophysiology, clinical phenotypes, and management Eur J Heart Fail 2017 Apr;19(4):479489 doi: 10.1002/ejhf.708 Epub 2016 Dec 20 PMID: 28000341 183 Kremastinos DT, Farmakis D Iron overload cardiomyopathy in clinical practice Circulation 2011; 124:22532263 184 Diller GP, Kempny A, Alonso-Gonzalez R et al Survival prospects and circumstances of death in contemporary adult congenital heart disease patients under follow-up at a large tertiary centre Circulation 2015;132:21182125 185 Baumgartner H, De Backer J, Babu-Narayan SV et al 2020 ESC Guidelines for the management of adult congenital heart disease Eur Heart J 2021 Feb 11;42(6):563-645 doi: 10.1093/eurheartj/ehaa554 186 Van Spall HGC, Rahman T, Mytton O, Ramasundarahettige C, Ibrahim Q, Kabali C, Coppens M, Brian Haynes R, Connolly S Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network metaanalysis Eur J Heart Fail 2017;19:1427-1443 187 Jonkman NH, Westland H, Groenwold RH, Agren S, Anguita M, Blue L, Bruggink-Andre de la Porte PW, DeWalt DA, Hebert PL, Heisler M, Jaarsma T, Kempen GI, Leventhal ME, Lok DJ, Martensson J, Muniz J, Otsu H, PetersKlimm F, Rich MW, Riegel B, Stromberg A, Tsuyuki RT, Trappenburg JC, Schuurmans MJ, Hoes AW What are effective program characteristics of selfmanagement interventions in patients with heart failure? An individual patient data metaanalysis J Card Fail 2016;22:861-871 152 188 Ekman I, Wolf A, Olsson LE, Taft C, Dudas K, Schaufelberger M, Swedberg K Effects of person-centred care in patients with chronic heart failure: the PCCHF study Eur Heart J 2012;33:1112-1119 189 Riegel B, Bennett JA, Davis A, Carlson B, Montague J, Robin H, Glaser D Cognitive impairment in heart failure: issues of measurement and etiology Am J Crit Care 2002;11:520528 190 Taylor RS, Walker S, Smart NA, Piepoli MF, Warren FC, Ciani O, Whellan D, O’Connor C, Keteyian SJ, Coats A, Davos CH, Dalal HM, Dracup K, Evangelista LS, Jolly K, Myers J, Nilsson BB, Passino C, Witham MD, Yeh GY, ExTraMATCH II Collaboration Impact of exercise rehabilitation on exercise capacity and quality-of-life in heart failure: individual participant meta-analysis J Am Coll Cardiol 2019;73:1430-1443 191 Lund LH, Carrero JJ, Farahmand B, Henriksson KM, Jonsson A, Jernberg T, Dahlstrom U Association between enrolment in a heart failure quality registry and subsequent mortality–a nationwide cohort study Eur J Heart Fail 2017;19:1107-1116 192 Brahmbhatt DH, Cowie MR Remote management of heart failure: an overview of telemonitoring technologies Card Fail Rev 2019;5:86-92 193 Inglis SC, Clark RA, Dierckx R, Prieto-Merino D, Cleland JG Structured telephone support or non-invasive telemonitoring for patients with heart failure Heart 2017;103:255-257 194 Morgan JM, Kitt S, Gill J, McComb JM, Ng GA, Raftery J, Roderick P, Seed A, Williams SG, Witte KK, Wright DJ, Harris S, Cowie MR Remote management of heart failure using implantable electronic devices Eur Heart J 2017;38:23522360 195 Dierckx R, Inglis SC, Clark RA, Prieto-Merino D, Cleland JG Telemedicine in heart failure: new insights from the Cochrane meta-analyses Eur J Heart Fail 2017;19:304306 153 HỘI TIM MẠCH HỌC QUỐC GIA VIỆT NAM Địa chỉ: 78 đường Giải Phóng, Đống Đa, Hà Nội Tel: (84-024) 8688 488 Fax: (84-024) 8688 488 Email: infor@vnha.org.vn Website: www.vnha.org.vn ... chứng suy tim xảy nghỉ ngơi, vận động thể lực nhẹ làm triệu chứng gia tăng Độ IV 3. 1.1 Suy tim cấp suy tim mạn Suy tim thường chia thành hai thể: suy tim mạn tính suy tim cấp tính Suy tim mạn... nghĩa tồn cầu suy tim Hình Nồng độ peptide niệu trợ giúp chẩn đoán suy tim Hình Qui trình chẩn đốn suy tim Hình Qui trình điều trị suy tim phân suất tống máu giảm Hình Điều trị suy tim phân suất... suy tim mạn đa chuyên khoa (QLSTĐCK) 135 13. 1 Phòng ngừa suy tim 135 13. 2 Các mơ hình chăm sóc . 135 13. 3 Nguyên tắc thành phần Chương trình quản lý suy tim 135